Xibrom Combination Therapy With Lucentis Successful

Armen Hareyan's picture
Advertisement

Calvin A. Grant, MD, Retina Macular Care, presented the results from his 60-patient retrospective case control study that was designed to evaluate the adjuvant use of Xibrom (bromfenac ophthalmic solution) 0.09% in Lucentis (ranibizumab) treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) in an oral poster presentation at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement